Lumen Technologies enters the post-earnings week having given back some of its pre-print momentum, with options traders and the Street now recalibrating around a stock that has run well past consensus targets.
The most striking shift this week is in options sentiment. Heading into the May 20 print, call positioning was near its most aggressive of the year — the put/call ratio was running close to 0.66, almost two standard deviations below its 20-day average. That conviction has unwound. The PCR now reads 0.67, still below its recent mean of 0.82, but the directional shift is notable: the ratio has climbed from a low near 0.66 earlier in the week, suggesting some of the call-side enthusiasm is fading. The 20-day mean is itself being pulled lower by the recent run of bullish positioning, which masks how far sentiment has rotated from late April, when the ratio was running above 0.90.
Short positioning tells a calmer story, consistent with what was true before the print. Short interest has eased to 5.45% of the float — down roughly 1.5% on the week and off the peaks of late April when it briefly touched close to 5.8%. Borrow costs are negligible at 0.36% annually, and availability is exceptionally wide at over 3,300% — meaning shares available to borrow dwarf the current short position by a factor of more than 33. Nothing in the lending market points to squeeze pressure. The ORTEX short score has drifted lower from 43.4 at the start of the month to 42.4, consistent with a gentle short-side retreat rather than any forced covering.
The Street's view remains structurally sceptical, even as targets have moved higher. In the week before earnings, JP Morgan, Wells Fargo, UBS, and TD Cowen all raised their price targets — to $7.00, $9.00, $8.00, and $9.00 respectively — while maintaining neutral or hold ratings across the board. The consensus mean target of $8.29 now sits below the current price of $9.19, meaning the stock has run past where even the freshly-raised targets are willing to go. The EV/EBITDA multiple has compressed to around 8.3x, down roughly 0.5x over the past 30 days as the enterprise value has shifted, but negative earnings and book value make traditional PE and PB metrics uninformative here. The EPS surprise factor score of 86 — near the top of the universe — is the one metric bulls can point to as evidence that management has consistently beaten low expectations.
Insider activity is worth flagging, though the picture is mixed. The 90-day net figure shows net proceeds of around $18.7 million, driven almost entirely by February sales from CEO Kathleen Johnson and CFO Chris Stansbury at prices around $7.11 — well below the current level. Johnson did buy roughly 79,000 shares at $6.35 in early February, a relatively modest open-market purchase of around $500k. The only recent trade is a director sell of 22,922 shares at $10.34 on May 14. The overall pattern reads as executive monetisation after the stock recovered from its restructuring lows, rather than a directional signal about the outlook.
Among correlated peers, CCOI gained nearly 10% on the week and ASTS surged more than 20%, while GSAT slipped about 1%. LUMN's own 6% weekly gain sits in the middle of that range. The next confirmed earnings event is July 28, which now becomes the focal point for whether the enterprise transformation narrative — and the Street's reluctant target upgrades — can catch up with a stock trading above every current published target.
See the live data behind this article on ORTEX.
Open LUMN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
